Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · IEX Real-Time Price · USD
21.98
-0.12 (-0.54%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for RCKT stock have an average target of 51.7, with a low estimate of 35 and a high estimate of 65. The average target predicts an increase of 135.21% from the current stock price of 21.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RCKT stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +141.13% | Apr 10, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $39 | Hold | Initiates | $39 | +77.43% | Apr 2, 2024 |
| UBS | UBS | Strong Buy Maintains $56 → $54 | Strong Buy | Maintains | $56 → $54 | +145.68% | Mar 1, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $50 | Buy | Maintains | $55 → $50 | +127.48% | Feb 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $65 | Buy | Maintains | $65 | +195.72% | Feb 27, 2024 |
Financial Forecast
Revenue This Year
27.57M
Revenue Next Year
166.54M
from 27.57M
Increased by 504.04%
EPS This Year
-2.71
from -2.92
EPS Next Year
-1.88
from -2.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 109.1M | 342.1M | 878.2M | 3.4B | 3.7B |
| Avg | 27.6M | 166.5M | 500.8M | 1.4B | 1.8B |
| Low | 784,000 | 22.6M | 185.7M | 343.0M | 777.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,140.8% | 427.3% | 580.3% | 161.2% |
| Avg | - | 504.0% | 200.7% | 183.0% | 30.0% |
| Low | - | -17.9% | 11.5% | -31.5% | -45.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.56 | -0.11 | 2.29 | 16.96 | 17.27 |
| Avg | -2.71 | -1.88 | -0.35 | 4.73 | 6.67 |
| Low | -3.31 | -3.11 | -1.34 | -1.68 | 0.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 265.3% |
| Avg | - | - | - | - | 41.2% |
| Low | - | - | - | - | -82.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.